WO2001032139A2 - Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained - Google Patents
Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained Download PDFInfo
- Publication number
- WO2001032139A2 WO2001032139A2 PCT/EP2000/011236 EP0011236W WO0132139A2 WO 2001032139 A2 WO2001032139 A2 WO 2001032139A2 EP 0011236 W EP0011236 W EP 0011236W WO 0132139 A2 WO0132139 A2 WO 0132139A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- lipid
- cisplatin
- aggregates
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a new method for the formulation of substances having a low water- solubility and lipophilicity in general and cisplatin in particular.
- the invention further relates to the formulation thus obtained.
- cis-Diamminedichloroplatinum(II) (cisplatin) is one of the most widely used agents in the treatment of solid tumors, and particularly effective against testicular and ovarian cancers.
- expansion of the clinical utility of cisplatin has been limited by its toxicity, as well as by the occurrence of intrinsic and acquired resistance in many common tumor types, the toxic side effects associated with the clinical use of cisplatin include nausea and vomiting, nephrotoxicity, ototoxicity, neuropathy and myelosuppression.
- cisplatin is a highly reactive molecule that interacts with a variety of extracellular as well as intracellular biomolecules.
- sulphur- and nitrogen-donor atoms have a high affinity for cisplatin.
- cisplatin binds extensively to plasma and tissue proteins which leads to a fast reduction in bioavailability and in the effective inactivation of a large part of the administered dose.
- In vitro studies indicate that 96% of cisplatin is bound to plasma proteins within 24 hrs.
- the remaining non- complexed or free cisplatin enters the cell by a combination of passive diffusion and protein-mediated uptake, and then interacts with intracellular substrates: thiols such as glutathione, methionine-containing proteins and peptides, and with the guanine bases in RNA and DNA. Only a few percent of the cisplatin entering the cell is able to bind to DNA.
- cisplatin and many of its analogs faces three major problems, (i) serious dose- limiting toxicities in particular nephrotoxicity and neurotoxicity, (ii) rapid inactivation of the drug as a result of complexation to plasma and tissue proteins, and (iii) the frequent occurrence of platinum resistance.
- these problems can be reduced by shielding of a drug from the extracellular environment by means of a lipid coating, such as the so-called liposomes.
- Liposomes are micro-particulate or colloidal carriers, typically 0.05-5.0 ⁇ m in size which form spontaneously when certain lipids are hydrated in aqueous media.
- Liposomes are composed of relatively biocompatible (non-toxic) and biodegradable material, and consist of an aqueous volume entrapped by one or more bilayers of natural and/or synthetic lipids. Depending on their lipophilicity, drugs can be encapsulated in the phospholipid bilayer, in the aqueous compartment or at the bilayer interface.
- the liposomes After intravenous, interstitial or intracavitary administration, the liposomes in general interact with cells of the target organ resulting in the local release of the encapsulated drug.
- the drug is either released extracellularly, after destabilisation of the liposomal carrier at the cell surface, or intracellularly, after endocytic uptake of the carrier by the target cell.
- Liposomes have been used as carriers of numerous pharmacologically active agents, such as antineoplastic and antimicrobial drugs, steroids, vaccines and genetic material.
- this approach fails because of inefficient encapsulation of the drug in lipid formulations resulting in low drug uptake by the tumor.
- a method that is based on one or more freezing and thawing cycles of a concentrated solution of cisplatin in the presence of negatively charged phospholipids generates small aggregates ("nanoparticles") of cisplatin covered by a single (and occasionally two or three) lipid bilayer (s) .
- the lipid- coated nanoparticles of cisplatin have an unprecedented drug-to-lipid ratio and an in vitro cytotoxicity up to 1000-fold higher than the free drug.
- the encapsulation efficiency of 1-4 mg cisplatin per ⁇ ol lipid is extremely high.
- cisPt-PS/-PC The resulting cisplatin-containing lipid suspension (cisPt-PS/-PC) was extremely cytotoxic with an IC 50 of ⁇ 2 nM as compared to 0.5 ⁇ M for the free drug (conventional cisplatin).
- a lipid suspension not loaded with cisplatin (blank) was not cytotoxic, and mixing conventional cisplatin with the blank lipid suspension did not result in an increase in cytotoxicity of cisplatin.
- the present invention therefore relates to a method for encapsulating substances, in particular drugs, that have a low water-solubility and lipophilicity, which method comprises: a) providing a lipid system comprising one or more negatively charged lipid (s) ; b) combining the lipid system with the substance (s) in a medium at a low total solutes concentration ; c) subjecting the mixture thus obtained to one or more cycles of freezing and thawing to produce lipid- coated aggregates of the substance (s) ; and d) optionally removing the free (non-enclosed) substance (s) .
- the invention can be applied for single substances or for mixtures of substances.
- the medium having a low total solutes concentration is preferably a medium having a maximum total solutes concentration of 0.1 molar. More preferably the total solutes concentration is not more than 0.02 molar.
- the substance (s) is (are) used in a high concentration.
- a high concentration is a concentration that does not lead to the formation of macromolecular aggregates of the substance (s) in the solution of the substance (s) , i.e. before the freeze thaw cycle.
- the concentration lies close to the solubility limit of the substance(s) , wherein "close” means either closely below or closely above the solubility limit.
- concentrations well above the solubility limit may under certain conditions still be suitable, provided that no macromolecular aggregates exist in the starting solution of the substance. Very small aggregates may however serve as nucleation sites for aggregate formation of the invention and are as such also allowed in the medium.
- solubility limit of a substance depends on various parameters, such as the medium used, the pH and the temperature. It is clear that the solubility limit intended here is the limit existing at the conditions used in the method of the invention.
- the lipid system can be a single or a mixed system.
- the latter system comprises at least 20 mol%, preferably 50 mol% negatively charged lipid(s) .
- the lipid system can take the form of a film, but preformed liposomes are equally well suited.
- Combining the lipid system with the drug can thus be effected by hydrating a dry film of the lipid system with a solution of the drug.
- the dry lipid film is first hydrated to obtain preformed liposomes after which the drug is added. Both methods lead to similar results.
- At least one cycle of freezing and thawing is necessary, but multiple cycles, preferably 5 or more typically 10 are also possible.
- the method of the invention may further comprise the step of isolating the lipid-coated drug aggregates e.g. by high-speed centrifugation (pelleting) through sucrose cushions, or, alternatively, by low-speed centrifugation in the absence of sucrose cushions.
- the method of the invention is in particular useful when the substance is the drug cisplatin.
- Other substances that can be encapsulated by the method of the invention are poorly water-soluble hydrophilic substances such as the magnetic resonance and X-ray imaging agents based on Europium or Gadolinium.
- the lipids in the mixture are preferably phosphatidylserine (PS) and phosphatidylcholine (PC) , carrying dioleoyl fatty acids.
- the acyl chains are other unsaturated or saturated fatty acids , or other aliphatic hydrocarbons.
- Alternative negatively charged lipids are phosphatidic acid (PA) , phosphatidylglycerol (PG) , phosphatidylinositol (PI) , and other negatively charged amphiphiles.
- Alternative neutral lipids are phosphatidylethanolamine (PE) , PE derivatized to polyethyleneglycol or to other hydrophilic polymers, sphingomyelin (SM) , and cholesterol, and other net neutral amphiphiles.
- the solution containing the substance to be encapsulated, in particular a drug may be a buffered solution of an approximately neutral pH, in particular a pH of about 7.4.
- the substance may be dissolved in water.
- helper substance may be present in the drug solution.
- the helper substance is preferably positively charged. Conditions of the method should be chosen at which positively charged species of the substance (or helper substance) are present.
- freeze-thaw cycles may be effected in manners known to the skilled person, but a practical mode comprises freezing in ethanol/dry ice and thawing in a waterbath of 37 °C.
- the dry lipid film can be provided according to methods known in the art, as for example described in D. Lichtenberg, and Y. Barenholz (1988) Liposomes: preparation, characterization, and preservation. Methods Biochem. Anal. 33, 337-462.
- Removal of the extravesicular drug can suitably be effected by repeated centrifugation and resuspension of the membrane pellet in an appropriate medium such as the medium (buffer, water) in which the drug was dissolved.
- an appropriate medium such as the medium (buffer, water) in which the drug was dissolved.
- the nanoparticle formation of the present invention is explained by the following mechanism (Fig. 5) : a nearly saturated solution of cisplatin in H 2 0, in the absence of added chloride, contains a mixture of the neutral dichloride- and dihydroxo-species of cisplatin which have a low solubility in water, and positively charged aquo-species of cisplatin with a much higher solubility.
- solutes are excluded from the expanding ice phase and cisplatin is progressively concentrated in the residual fluid.
- the solubility limit of the neutral species of cisplatin is exceeded first and small aggregates form, which are subsequently covered by positively charged aquo-species of cisplatin.
- the highly positively charged cisplatin aggregates interact with the negatively charged lipid vesicles, and membranes reorganize to cover the surface of the aggregates resulting in lipid-coated nanoparticles of cisplatin. Only those aggregates of cisplatin that are completely covered by lipid, do not redissolve upon thawing.
- nanoparticle formation requires the presence of both negatively charged lipids and cisplatin, and critically depends on freeze-thawing.
- PS can be replaced by phosphatidic acid (PA) , and the same results are obtained adding cisplatin to a dry lipid film or to preformed liposomes.
- PA phosphatidic acid
- high concentrations of salts such as NaN0 3 , which prevent phase separation of ice and solutes and thus aggregation of cisplatin during freezing, strongly inhibits nanoparticle formation.
- the lipid coat prevents the reaction of cisplatin with substrates present in the extracellular environment and at the cell surface.
- the lipid coating is either destabilized upon interacting with the cell surface, or, after endocytic uptake by the tumour cell (Fig. 5) .
- Lipolytic enzymes present in the endosomal system digest the lipid-coat and release cisplatin, which, after crossing the endosomal membrane, ultimately interacts with nuclear DNA triggering cell death.
- the amount of cisplatin encapsulated in the formulations of the invention is 2-3 orders of magnitude higher than that of any lipid formulation of cisplatin mentioned in the literature to date (Newman, M. S., Colbern, G. T. , Working, P. K. , Engbers, C. & Amantea, M. A. (1999) Cancer Chemother. Pharmacol. 43, 1-7; Sur, B. , Ray, R. R. , Sur, P. & Roy, D. K. (1983) Oncology 40, 372- 376; Steerenberg, P. A., Storm, G., de, G. G. , Claessen, A., Bergers, J. J., Franken, M. A. M.
- the lipid- coated nanoparticles have an extremely high anti-tumor activity in vitro, up to 1000-fold higher than that of the free drug.
- Lipid composition, surface charge, and size distribution of the lipid-coated nanoparticles can be manipulated and optimized for use in vivo as an anti- cancer formulation.
- the method of the invention can overcome these problems.
- a particularly promising embodiment of the invention involves freeze-thawing a mixture of a poorly water-soluble neutral drug with a more water-soluble helper substance carrying a positive charge, in the presence of negatively charged phospholipids. During freezing, the solubility limit of the drug is exceeded first, and small aggregates form which are subsequently coated by the positively charged helper substance.
- Alternative embodiments of the method of the invention comprise the use of other amphipathic molecules instead of lipids and the induction of aggregates in other ways.
- These other ways of aggregation include the use of an oversaturated solution of the substance to be encapsulated and the addition of nucleation sites thereto.
- These two variants can be either used separately or be combined in the method as claimed.
- the invention also relates to a formulation of a substance that is poorly water-soluble and has a low lipophilicity, obtainable by the method as claimed.
- the substance takes the form of aggregates thereof coated with one or more bilayer (s) of lipids.
- the majority of the aggregates are coated with one bilayer of lipids.
- the formulation is a formulation of cisplatin, wherein the cisplatin takes the form of aggregates coated with one or more bilayer(s) of lipids. Preferably the majority of the aggregates are coated with one bilayer of lipids.
- the aggregates of cisplatin are preferably of an elongated shape measuring about 40-50, more in particular about 46 nm by 80 to 90, more in particular about 86 nm (lipid coat inclusive) .
- Such cisplatin formulation is for example obtainable by the method of the invention.
- the present invention will be further elucidated in the following example that is directed to the drug cisplatin.
- the invention is however more broadly applicable to other substances, such as drugs, that have a low water-solubility and low lipophilicity.
- Fig. 1 Cytotoxicity towards human ovarian carcinoma cells.
- A Lipid suspension of cisplatin (cisPt-PS/PC;
- A) conventional cisplatin (I) , conventional cisplatin mixed with a blank (cisplatin-free) lipid suspension (D; same lipid concentration as in ⁇ ), blank lipid suspension (dashed line) .
- the cytotoxicity of conventional cisplatin (I) is not influenced by FT (D) .
- Fig. 2 Morphology and subfractionation.
- A) Cryo-EM of cisPt-PS/PC reveals nanoparticles of cisplatin (marked by asterisk; MLV, multilamellar vesicle) .
- FIG. 4 Cytotoxicity and sizing of cisplatin nanoparticles .
- A Cytotoxicity of conventional cisplatin ( ⁇ ) , and of isolated nanoparticles before ( * ⁇ ) and after ( ⁇ ) sizing.
- Lipid formulations of cisplatin Cisplatin (Sigma, St. Louis, MO) was dissolved in Pipes-EGTA buffer (10 mM Pipes-NaOH, 1 mM EGTA, pH 7.4) or MilliQ water and incubated in the dark overnight at 37 °C to ensure full equilibration.
- Lipid dispersions (1.2 mM) were prepared by adding 5 mM cisplatin to a dry film of phospholipids (Avanti Polar Lipids, Inc., Birmingham, AL) , incubating at 37°C for 15 minutes, followed by 10 freeze-thaw (FT) cycles using ethanol/dry- ice (-70"C) and a water bath (37°C).
- Free (extravesicular) cisplatin was removed by repeated centrifugation (3-times, TLA 120.2, 40,000 rpm, 10 in, 20°C; Beckman Coulter, Inc., CA) , resuspending the membrane pellet in Pipes-EGTA buffer.
- a cisplatin-lipid dispersion in MilliQ water (1 ml) was loaded on top of a step gradient consisting of 1 ml each of 1.8 M, 0.6 M, and 0.2 M sucrose in Pipes-EGTA buffer, centrifuged (SW 60, Beckman Coulter, Inc., 55,000 rpm, 30 min, 4°C), and the pellet resuspended in MilliQ water. Filtered pellet fractions were obtained after high-pressure extrusion (Hope, M. J., Bally, M. B. , Mayer, L. D. , Janoff, A. S. & Cullis, P. R. (1986) Chem. Phvs. Lipids 40, 89-107) through polycarbonate filters (200 nm pore size) , and reisolation of the pellet by sucrose gradient centrifugation.
- Hope M. J., Bally, M. B. , Mayer, L. D. , Janoff, A. S. &
- the phospholipid content was determined as described in (Rouser, G. , Fleischer, S. & Yamamoto, A. (1970) Lipids 5, 494-496) , and cisplatin was quantified by flameless atomic absorption spectroscopy, using a modifier solution of 0.5 % Triton X-100 in water, and K 2 PtCl 6 (Sigma, St. Louis, MO) as a standard.
- Human-derived ovarian tumor cells IGROV-1 were grown on plastic in RPMI (Gibco, Glasgow, UK) supplemented with 25mM Hepes, 10% FCS, and 1% PenStrep. Cell lines were free of ycoplasma infections.
- Formulations of cisplatin were diluted in RPMI without FCS to a cisplatin concentration of 233 ⁇ M. Tumor cell growth inhibition was determined using 96-wells plates and the sulforhodamine-B assay (Skehan, P. , Storeng, R. , Scudiero, D. , Monks, A., McMahon, J., Vistica, D. , Warren, J. T. , Bokesch, H. , Kenney, S. & Boyd, M. R. (1990) J. Natl . Cancer Inst. 82, 1107-1112). Approximately 1000 cells were seeded per well, the cisplatin formulations were added after 48 h (20 concentrations, in triplicate) , and the cells further incubated for 120 h at 37 °C.
- Cisplatin-lipid dispersions were visualized using bare- or lacey carbon grids, vitrification in melting ethane, and cryo-electron microscopy (cryo-EM) at low dose according to (Frederik, P. M. , Stuart, M. C. ,
- Negative stain EM was performed using uranyl acetate following standard procedures .
- Diaquated cisplatin was prepared as described in (Appleton, T. G. , Berry, R. D. , Davis, C. A., Hall, J. R. & Kimlin, H. A. (1984) Inor ⁇ . Chem. 23, 3514-3521) by incubating cisplatin with AgN0 3 . Large unilamellar vesicles were prepared by extrusion according to (Hope et al. (1986), supra) . Dynamic light scattering analysis of particle size was performed using a Zetasizer 3000 (Malvern Instruments Ltd., Malvern, UK).
- the method of the present invention involves hydration of a dry lipid film composed of equimolar amounts of dioleoyl-phosphatidylserine (PS) and dioleoyl- phosphatidylcholine (PC) , with a buffered solution (pH 7.4) of 5 mM cisplatin followed by one or more, preferably 10 freeze-thaw (FT) cycles, and removal of free (extravesicular) cisplatin by centrifugation.
- PS dioleoyl-phosphatidylserine
- PC dioleoyl- phosphatidylcholine
- FT freeze-thaw
- cisPt-PS/PC was extremely cytotoxic (Fig. 1A) with a typical IC 50 , the drug concentration at which cell growth is inhibited by 50%, of -2 nM as compared to 0.5 ⁇ M for the free drug (conventional cisplatin) .
- a lipid suspension not loaded with cisplatin (blank) was not cytotoxic, and mixing conventional cisplatin with the blank lipid suspension did not increase the cytotoxicity of cisplatin.
- Lipid-coated nanoparticles of cisplatin Lipid-coated nanoparticles of cisplatin
- This value by far exceeded the solubility limit of cisplatin (-8 mM in chloride-free media (cf. Riley, C. M. & Sternson, L. A. (1985) Analytical profiles of drug substances 14, 78- 105) , and suggested that the lipid formulations contained aggregates of cisplatin. Indeed, cryo-EM examination (Fig.
- EM analysis of the gradient fractions showed that the pellet fraction existed of lipid-coated nanoparticles (Fig. 2C) , and that lipid vesicles were virtually absent (data not shown) .
- the majority of the particles was bean-shaped measuring 46 ⁇ 16 nm by 86 ⁇ 32 nm (lipid coat inclusive) .
- Negative stain EM showed electron-dense nanoparticles surrounded by a bright layer not accessible to the stain (Fig. 2D) .
- This bright layer corresponds to the hydrated lipid coating.
- a single bilayer coat would be expected to have a thickness of ⁇ 6.6 nm, while a coat consisting of two bilayers should be at least 10.4 nm thick (based on a bilayer thickness of 3.8 nm and a water layer of 2.8 nm; cf. Lewis, B. A. & Engelman, D. M. (1983) J. Mol. Biol. 166, 211-217).
- the thickness of the layer 5-9 nm for -80% of the particles, indicated that most nanoparticles of cisplatin were coated by a single lipid bilayer.
- Disruption of the lipid coat leads to the immediate dissolution of the lipid-coated nanoparticles: resuspension of the pellet resulted in a colloidal solution with a milky appearance, which immediately turned transparent upon addition of detergent (Fig. 3B) .
- the cytotoxicity of the pellet fraction was much greater than that of conventional cisplatin, and could be further enhanced by filtering the pellet fraction (Fig. 4A) .
- Nanoparticle formation was determined by sucrose density centrifugation as the amount of cisplatin in the pellet fraction relative to that in the control pellet (PS/PC, 5 mM cisplatin in H 2 0, FT): >70% (+) , 15-50% (+/")/ ⁇ 10% (-) ⁇ Visual inspection.
- Control pellet PS/PC, 5 mM cisplatin in H 2 0, FT
- Cisplatin added to preformed liposomes unilamellar or multilamellar
- ⁇ 5 mM cisplatin in H 2 0 has pH 5.5 and contains -10 % diaquated (aquo/hydroxo) species of cisplatin.
- PA dioleoyl-phosphatidic acid
- PG -phosphatidylglycerol
- PE -phosphatidylethanolamine
- SM sphingomyelin
- Choi cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002389147A CA2389147A1 (en) | 1999-11-05 | 2000-11-06 | Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained |
AU21584/01A AU2158401A (en) | 1999-11-05 | 2000-11-06 | Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained |
JP2001534344A JP2003513030A (en) | 1999-11-05 | 2000-11-06 | Method for encapsulating substances exhibiting low water solubility and lipophilicity and preparations obtained by this method |
EP00985023A EP1225871A2 (en) | 1999-11-05 | 2000-11-06 | Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99203673.1 | 1999-11-05 | ||
EP99203673 | 1999-11-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001032139A2 true WO2001032139A2 (en) | 2001-05-10 |
WO2001032139A3 WO2001032139A3 (en) | 2001-12-13 |
Family
ID=8240830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/011236 WO2001032139A2 (en) | 1999-11-05 | 2000-11-06 | Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1225871A2 (en) |
JP (1) | JP2003513030A (en) |
AU (1) | AU2158401A (en) |
CA (1) | CA2389147A1 (en) |
WO (1) | WO2001032139A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002443A1 (en) * | 2002-06-26 | 2004-01-08 | Tuo Jin | Solid dosage forms for rapid dissolution of poorly soluble drugs |
FR2924430A1 (en) * | 2007-11-30 | 2009-06-05 | Univ Bordeaux 2 | PROCESS FOR THE PREPARATION OF NANOPARTICLES BASED ON FUNCTIONAL AMPHIPHILIC MOLECULES OR MACROMOLECULES AND THEIR USE |
WO2010136676A1 (en) | 2009-05-29 | 2010-12-02 | Universite Victor Segalen Bordeaux 2 | Functional amphiphilic molecule or macromolecule formulations with multiple compartments |
US9186322B2 (en) | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
US11291644B2 (en) | 2012-09-04 | 2022-04-05 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0290296A2 (en) * | 1987-03-05 | 1988-11-09 | The Liposome Company, Inc. | Liposomal formulations with a high antineoplastic agent/lipid ratio |
DE4341472A1 (en) * | 1993-12-02 | 1995-06-08 | Schering Ag | A method for increasing the stability of liposome suspensions containing hydrophilic drugs |
US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
-
2000
- 2000-11-06 WO PCT/EP2000/011236 patent/WO2001032139A2/en not_active Application Discontinuation
- 2000-11-06 JP JP2001534344A patent/JP2003513030A/en active Pending
- 2000-11-06 AU AU21584/01A patent/AU2158401A/en not_active Abandoned
- 2000-11-06 EP EP00985023A patent/EP1225871A2/en not_active Withdrawn
- 2000-11-06 CA CA002389147A patent/CA2389147A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
EP0290296A2 (en) * | 1987-03-05 | 1988-11-09 | The Liposome Company, Inc. | Liposomal formulations with a high antineoplastic agent/lipid ratio |
DE4341472A1 (en) * | 1993-12-02 | 1995-06-08 | Schering Ag | A method for increasing the stability of liposome suspensions containing hydrophilic drugs |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, vol. 108, no. 2, 11 January 1988 (1988-01-11) Columbus, Ohio, US; abstract no. 11127, STEERENBERG, P. A. ET AL: "Liposomes as a drug carrier system for cis- diamminedichloroplatinum* * (II). I. Binding capacity, stability and tumor cell growth inhibition in vitro" XP000998413 & INT. J. PHARM. (1987), 40(1-2), 51-62 , 1987, * |
CHEMICAL ABSTRACTS, vol. 111, no. 10, 4 September 1989 (1989-09-04) Columbus, Ohio, US; abstract no. 84008, KALEDIN, V. I. ET AL: "Inhibition of tumor growth in the liver by cisplatin encapsulated in large oligolamellar liposomes prepared by freezing and thawing" XP000998106 & VOPR. ONKOL. (1989), 35(5), 599-602 , 1989, * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002443A1 (en) * | 2002-06-26 | 2004-01-08 | Tuo Jin | Solid dosage forms for rapid dissolution of poorly soluble drugs |
US9186322B2 (en) | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
FR2924430A1 (en) * | 2007-11-30 | 2009-06-05 | Univ Bordeaux 2 | PROCESS FOR THE PREPARATION OF NANOPARTICLES BASED ON FUNCTIONAL AMPHIPHILIC MOLECULES OR MACROMOLECULES AND THEIR USE |
WO2009098404A2 (en) * | 2007-11-30 | 2009-08-13 | Universite Victor Segalen Bordeeux 2 | Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof |
WO2009098404A3 (en) * | 2007-11-30 | 2009-11-12 | Universite Victor Segalen Bordeeux 2 | Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof |
US9533049B2 (en) | 2007-11-30 | 2017-01-03 | Universite D'aix-Marseille | Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof |
WO2010136676A1 (en) | 2009-05-29 | 2010-12-02 | Universite Victor Segalen Bordeaux 2 | Functional amphiphilic molecule or macromolecule formulations with multiple compartments |
US9050268B2 (en) | 2009-05-29 | 2015-06-09 | Universite D'aix-Marseille | Functional amphipilic molecule or macromolecule formulations with multiple compartments |
US11291644B2 (en) | 2012-09-04 | 2022-04-05 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
Also Published As
Publication number | Publication date |
---|---|
JP2003513030A (en) | 2003-04-08 |
EP1225871A2 (en) | 2002-07-31 |
CA2389147A1 (en) | 2001-05-10 |
WO2001032139A3 (en) | 2001-12-13 |
AU2158401A (en) | 2001-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Large et al. | Liposome composition in drug delivery design, synthesis, characterization, and clinical application | |
Mo et al. | PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure | |
JP7012124B2 (en) | Liposomal compositions and pharmaceutical compositions | |
Johnston et al. | Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin | |
Zeng et al. | Preparation and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline nanoparticles (LCNPs) for improved bioavailability | |
US5389377A (en) | Solid care therapeutic compositions and methods for making same | |
Nekkanti et al. | Recent advances in liposomal drug delivery: a review | |
WO2010009186A1 (en) | Liposome formulation having hydrophilic and hydrophobic pharmaceutical compounds co-encapsulated therein | |
US20020131995A1 (en) | Targeted drug delivery with a cd44 receptor ligand | |
AU2007341803A2 (en) | Liposomal pharmaceutical preparation and method for manufacturing the same | |
EP1448165B1 (en) | Lipid carrier compositions and methods for improved drug retention | |
Carmona-Ribeiro | Lipid bilayer fragments and disks in drug delivery | |
Zeng et al. | Lipid-coated ZnO nanoparticles as lymphatic-targeted drug carriers: study on cell-specific toxicity in vitro and lymphatic targeting in vivo | |
Li et al. | Stepwise targeting and responsive lipid-coated nanoparticles for enhanced tumor cell sensitivity and hepatocellular carcinoma therapy | |
US20030129224A1 (en) | Lipid carrier compositions and methods for improved drug retention | |
WO2017024312A1 (en) | Phospholipid-cholesteryl ester nanoformulations and related methods | |
CA2570329C (en) | Liposome preparation containing slightly water-soluble camptothecin | |
EP1225871A2 (en) | Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained | |
Sirisha et al. | Liposomes-the potential drug carriers | |
WO2010095964A1 (en) | A method for amphiphilic drug loading in liposomes by ion gradient | |
WO2000009071A2 (en) | A novel liposomal formulation useful in treatment of cancer and other proliferation diseases | |
US10925831B2 (en) | Liposomal formulations of platinum-acridine anticancer agents and methods thereof | |
Gupta et al. | Nanoliposome: An overview of types, preparation, evaluation and application. | |
Minh et al. | Developing and evaluating in vitro effect of pegylated liposomal doxorubicin on human cancer cells | |
Socaciu et al. | Simple and fast procedure to incorporate doxorubicine in small unilamellar liposomes: Effects on liposome size and zeta potential |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000985023 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2389147 Country of ref document: CA |
|
ENP | Entry into the national phase in: |
Ref country code: JP Ref document number: 2001 534344 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000985023 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000985023 Country of ref document: EP |